AU1157695A - Hybrid growth factors - Google Patents

Hybrid growth factors

Info

Publication number
AU1157695A
AU1157695A AU11576/95A AU1157695A AU1157695A AU 1157695 A AU1157695 A AU 1157695A AU 11576/95 A AU11576/95 A AU 11576/95A AU 1157695 A AU1157695 A AU 1157695A AU 1157695 A AU1157695 A AU 1157695A
Authority
AU
Australia
Prior art keywords
growth factors
hybrid growth
hybrid
factors
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11576/95A
Inventor
Jonathan I. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of AU1157695A publication Critical patent/AU1157695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Enzymes And Modification Thereof (AREA)
AU11576/95A 1990-09-28 1995-02-06 Hybrid growth factors Abandoned AU1157695A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58995890A 1990-09-28 1990-09-28
US589958 1990-09-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU87359/91A Division AU8735991A (en) 1990-09-28 1991-09-26 Hybrid growth factors

Publications (1)

Publication Number Publication Date
AU1157695A true AU1157695A (en) 1995-04-13

Family

ID=24360286

Family Applications (2)

Application Number Title Priority Date Filing Date
AU87359/91A Abandoned AU8735991A (en) 1990-09-28 1991-09-26 Hybrid growth factors
AU11576/95A Abandoned AU1157695A (en) 1990-09-28 1995-02-06 Hybrid growth factors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU87359/91A Abandoned AU8735991A (en) 1990-09-28 1991-09-26 Hybrid growth factors

Country Status (8)

Country Link
EP (1) EP0503050A4 (en)
JP (1) JPH05502463A (en)
AU (2) AU8735991A (en)
CA (1) CA2069746A1 (en)
IE (1) IE913426A1 (en)
PT (1) PT99107A (en)
WO (1) WO1992006116A1 (en)
ZA (1) ZA917766B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
DE69333243T2 (en) * 1992-11-24 2004-08-19 G.D. Searle & Co., Chicago MUTTED INTERLEUKIN-3 (IL-3) POLYPEPTIDES
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
WO1995028427A1 (en) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
ITFI940106A1 (en) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa HYBRID MOLECULE OF GM-CSF-L-EPO OR EPO-L-GM-CSF FORMULA FOR ERYTHROPOIETIC STIMULATION
IT1271688B (en) * 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
EP0783003B1 (en) * 1995-04-26 2006-11-22 Kyowa Hakko Kogyo Co., Ltd. G-CSF TPO fusion proteins
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
PT935752E (en) * 1996-09-20 2002-03-28 Ortho Mcneil Pharm Inc METHODS FOR THE DETERMINATION OF ERITROPOIETIN IN VITRO BIOACTIVITY
AU725547B2 (en) * 1996-10-25 2000-10-12 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
AU721196B2 (en) * 1996-10-25 2000-06-29 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ES2208798T3 (en) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh RECOMBINANT HUMAN ERYTHROPOYETIN WITH AN ADVANTAGE GLICOSILATION PROFILE.
WO1999041382A2 (en) * 1998-02-17 1999-08-19 Hyseq, Inc. A novel interleukin-3 and uses thereof
BR9917606A (en) * 1998-11-06 2002-12-31 Bio Sidus S A Procedure for the purification of recombinant human erythropoietin from cell culture supernatants and recombinant human erythropoietin obtained with such procedure
BRPI0110914B8 (en) 2000-05-15 2021-05-25 Hoffmann La Roche 'liquid pharmaceutical composition, process for its preparation and use of a pharmaceutical composition'
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
CN102906108B (en) 2010-03-04 2016-01-20 菲尼克斯公司 For preparing the method for solubility recombinant interferon albumen without sex change
PL2552949T3 (en) 2010-04-01 2017-01-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
EP2881414B1 (en) 2012-07-31 2018-07-11 Asahi Kasei Kabushiki Kaisha Epoxy resin composition and cured article
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2534222B2 (en) * 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ Fusion gene for mixed protein production
US4935352A (en) * 1985-10-21 1990-06-19 Takeda Chemical Industries, Ltd. Expression vector for animal cell line and use thereof
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0275300B1 (en) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Recombinant vaccine
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
DE69007975T2 (en) * 1989-08-22 1994-07-21 Immunex Corp FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3.
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators

Also Published As

Publication number Publication date
JPH05502463A (en) 1993-04-28
WO1992006116A1 (en) 1992-04-16
EP0503050A1 (en) 1992-09-16
PT99107A (en) 1992-08-31
ZA917766B (en) 1993-03-29
CA2069746A1 (en) 1992-03-29
IE913426A1 (en) 1992-04-08
EP0503050A4 (en) 1994-07-06
AU8735991A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
AU1157695A (en) Hybrid growth factors
AU7937791A (en) Culture bag
AU639126B2 (en) Oxorapamycin
AU614482B3 (en) Receptacle
AU8791591A (en) Tnf-muteins
AU7846991A (en) Aminobenzodiazepines
AU2738392A (en) Novel hybrid transforming growth factors
AU9030991A (en) Improved capacitor-sensor
AU7956191A (en) Transportsystem
AU7804691A (en) N-pyridinesulfonyl-N-pyrimidinyl-or-triazinylureas
AU8764191A (en) Ibuprofen-antihistamine combinations
AU3921993A (en) Novel antler-derived bone growth factors
AU7726391A (en) Slitterscorer
AU617287B3 (en) Receptacle
AU640295B2 (en) Containers
AU8143891A (en) Boxes
AU8740291A (en) 3d-spectacles
AU7566691A (en) Compostor
AU7587991A (en) Electrodermatome
AU8443991A (en) Clear topped composter
AU8984191A (en) Thiadiazinones
AU7922191A (en) 2-acylamino-7-chlorobenzothiazoles
AU8710691A (en) Ibuprofen-diuretic combinations
AU7296291A (en) Carrier
AU7412191A (en) Produce storage